Trizipin (meldonium) coated tablets 250 mg. №40 vial

Description

Trizipin (meldonium) coated tablets 250 mg. №40 vial

Composition

active substance: meldonium;

1 tablet contains 250 mg of 3- (2,2,2-trimethylhydrazinium) propionate dihydrate;

Excipients: potato starch, povidone, crospovidone, colloidal anhydrous silica, magnesium stearate, hydroxypropylcellulose, talc, titanium dioxide (E 171), hydroxypropylmethylcellulose.

Dosage form

Tablets of white or white with a creamy tinge with a biconvex smooth surface, possibly with a specific odor, coated with a film coating.

Pharmacotherapeutic group

Other cardiac drugs. Meldonium.
С01Е В22.

Pharmacological properties

It is a remedy that improves metabolic processes in the heart muscle. In conditions of ischemia (insufficient blood supply), it restores the cellular balance between oxygen consumption and its delivery, prevents disruption of ATP transport, activates glycolysis without additional oxygen consumption. It helps to increase performance, reduce the severity of signs of physical and mental overstrain, activate immunity. Has a cardioprotective effect. In case of acute ischemic myocardial injury, it reduces the area of ​​necrosis and shortens the rehabilitation period.

Indications

Trizipin tablets is used:

• with diseases of the heart, vascular system (chronic insufficiency, stable exertional angina, cardiomyopathy, functional disorders);
• with acute / chronic disorders of cerebral circulation;
• with reduced performance, psychoemotional or physical overstrain;
• during the recovery period after head injuries, cerebrovascular disorders, encephalitis.

Contraindications

Trizipin tablets is contraindicated:

• with intolerance to the components of the drug;
• with increased intraocular pressure;
• with severe dysfunction of the liver, kidneys.

Application during pregnancy and lactation

Contraindicated.

Method of application and dosage

For internal use. Due to the possible stimulating effect of the drug is recommended to use in the morning.

Diseases of the heart and vascular system, cerebrovascular disorders.

The dose is 500-1000 mg per day. The daily dose can be used all at once or divided into 2 doses. The maximum daily dose is 1000 mg.

Reduced efficiency, overexertion and recovery period.

The dose is 500 mg per day. The daily dose can be used all at once or divided into two single doses. The maximum daily dose is 500 mg.

The duration of treatment is 4-6 weeks. The course of treatment can be repeated 2-3 times a year.

Overdose

The drug is low toxic.
Possible symptoms: decreased blood pressure, tachycardia, dizziness, weakness.
Treatment is symptomatic. Monitoring of kidney and liver function is necessary.

Side effects:

• Urinary disorders: pollakiuria.
• Immune disorders: allergic dermatitis, urticaria, angioedema, anaphylactic reactions.
• Mental disorders: sleep disturbances, fear, agitation, obsessive thoughts.
• Neurological disorders: paresthesia, cephalalgia, tremor, vertigo, hypesthesia, tinnitus, gait disturbance, loss of consciousness.
• Cardiovascular disorders: palpitations, cardiac arrhythmias, tachycardia, discomfort in the region of the heart, atrial fibrillation, instability of blood pressure, hyperemia, pallor of the skin, hypertensive crisis.
• Respiratory disorders: pharyngitis, cough, apnea, dyspnea.
• Gastrointestinal disorders: dyspepsia, loss of appetite, dysgeusia (metallic taste in the mouth), nausea, diarrhea, flatulence, hypersalivation, dry mouth.
• Dermatological disorders: macular, papular eruptions, itching.
• Musculoskeletal disorders: back pain, myasthenia gravis, muscle spasms.
• General: weakness, asthenia, chills, swelling of the legs, face, cold sweat, feeling hot or cold.
• Laboratory changes: increased levels of C-reactive protein, dyslipidemia, abnormalities in the electrocardiogram, eosinophilia, tachycardia.